Author
Listed:
- Thomas Kimman
(University Medical Center Utrecht)
- Marta Cuenca
(University Medical Center Utrecht)
- Ralph G. Tieland
(University Medical Center Utrecht)
- Dedeke Rockx-Brouwer
(University Medical Center Utrecht)
- Jasmijn Janssen
(University Medical Center Utrecht)
- Benjamin Motais
(University Medical Center Utrecht
University Medical Centre Utrecht)
- Anne Slomp
(University Medical Center Utrecht)
- Corine Pleijte
(University Medical Center Utrecht)
- Sabine Heijhuurs
(University Medical Center Utrecht)
- Angelo D. Meringa
(University Medical Center Utrecht)
- Wendy Boschloo
(University Medical Center Utrecht)
- Douwe MT Bosma
(University Medical Center Utrecht)
- Sanne Kroos
(University Medical Center Utrecht)
- Vania lo Presti
(University Medical Center Utrecht
Princess Máxima Center for Pediatric Oncology)
- Joost P. G. Sluijter
(University Medical Center Utrecht
Utrecht University)
- Stefan Nierkens
(University Medical Center Utrecht
Princess Máxima Center for Pediatric Oncology
Princess Máxima Center for Pediatric Oncology)
- Niels Bovenschen
(University Medical Center Utrecht
Utrecht University
University Medical Centre Utrecht)
- Jürgen Kuball
(University Medical Center Utrecht
University Medical Centre Utrecht
Utrecht University)
- Alain Mil
(University Medical Center Utrecht
Utrecht University)
- Monique C. Minnema
(University Medical Centre Utrecht
Utrecht University)
- Zsolt Sebestyén
(University Medical Center Utrecht
Utrecht University)
- Victor Peperzak
(University Medical Center Utrecht
Utrecht University)
Abstract
Clinical responses with chimeric antigen receptor (CAR) T cells are encouraging, but primary resistance and relapse after therapy prevent durable remission in many patients with cancer, with apoptosis resistance in cancer cells that limits killing by CAR T cells being a potential cause. Here we aim to boost tumor cell apoptosis induced by CAR T cells and find that anti-B cell maturation antigen (BCMA) CAR T cells over-expressing a granzyme B-NOXA fusion protein show improved killing of multiple myeloma (MM) cells in vitro and in xenograft mouse models in vivo. Mechanistically, such an enhancement is mediated by localizing NOXA to cytotoxic granules that are released into cancer cells upon contact. In MM cells, inhibition of MCL-1, an anti-apoptotic factor, by its natural ligand NOXA effectively induces apoptosis. Our data thus show that endowing granzyme B-NOXA expression to CAR T cells improves their killing efficacy, thereby presenting a potential generalizable enhancement for CAR T-mediated anti-cancer immunity.
Suggested Citation
Thomas Kimman & Marta Cuenca & Ralph G. Tieland & Dedeke Rockx-Brouwer & Jasmijn Janssen & Benjamin Motais & Anne Slomp & Corine Pleijte & Sabine Heijhuurs & Angelo D. Meringa & Wendy Boschloo & Douwe, 2025.
"Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation,"
Nature Communications, Nature, vol. 16(1), pages 1-12, December.
Handle:
RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-59818-8
DOI: 10.1038/s41467-025-59818-8
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-59818-8. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.